Published in Gene Therapy Weekly, December 28th, 2006
"We are very pleased to welcome Mr. Barr to Chromos' board of directors," said Darrell Elliott, chairman and director of Chromos. "David's extensive experience in helping companies achieve their potential, will bring immediate value to strategic planning at the board level."
Barr is currently the CFO and investment manager of PenderFund Capital Management Ltd. PenderFund is a shareholder of Chromos and a participant in the recent bridge loan financing. "I look forward to working with management in achieving the company's strategic goals...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.